RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $160 from $156 and keeps an Outperform rating on the shares after its Q3 earnings beat. The company’s Crenessity launch continues to impress, while Ingrezza came in ahead of expectations albeit with some pricing tradeoffs, the analyst tells investors in a research note. RBC adds that there could be some share volatility into the upcoming Austedo IRA announcement, but also notes that this presents a buying opportunity as the impact should be “manageable”.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $146 from $145 at Mizuho
- Neurocrine price target raised to $147 from $124 at BMO Capital
- Neurocrine price target raised to $179 from $175 at Piper Sandler
- Neurocrine price target raised to $164 from $160 at Canaccord
- Neurocrine price target raised to $203 from $175 at Citi